Apollo Endosurgery logo
Apollo Endosurgery APEN

Annual report 2022
added 03-30-2023

report update icon

Apollo Endosurgery Income Statement 2011-2026 | APEN

Annual Income Statement Apollo Endosurgery

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

403 M 167 M 94.9 M 64 M 70.3 M 83.3 M 5.12 M 5.15 M 47.2 M 64.1 M 53.1 M 59.8 M

Shares

40.7 M 30.2 M 22.8 M 21.5 M 19.8 M 13.6 M 390 K 334 K 215 K 175 K 139 K 117 K

Historical Prices

9.91 5.51 4.17 3.01 3.47 6.27 13 15.4 219 362 385 496

Net Income

-39.8 M -24.7 M -22.6 M -27.4 M -45.8 M -27.3 M -41.2 M -10 M -16.6 M -6.56 M -2.75 M -3.11 M

Revenue

76.9 M 63 M 42 M 50.7 M 60.9 M 64.3 M 64.9 M 1.6 M 5.08 M 7.99 M 6.69 M 9.39 M

Cost of Revenue

34.4 M 28 M 19.8 M 25 M 27.7 M 24.6 M 25.3 M 20.5 M - - - -

Gross Profit

42.4 M 35 M 22.2 M 25.7 M 33.2 M 39.7 M 39.6 M 1.6 M 5.08 M 7.99 M 6.69 M 9.39 M

Operating Income

-31.4 M -19.2 M -15.8 M -23.5 M -40.1 M -22.4 M -20.8 M -16.7 M -17.8 M -7.59 M -5.56 M -3.71 M

Interest Expense

4.67 M 8.32 M 5.25 M 4.05 M 4.06 M 4.51 M 18.2 M 10 M 18 26.6 K -90.7 K -4.09 K

EBITDA

-30.2 M -17.8 M -13.8 M -27 M -25.2 M -15.2 M -13.6 M -10.4 M -17.6 M -7.4 M -5.37 M -3.57 M

Operating Expenses

73.8 M 54.2 M 38 M 54.8 M 65.5 M 62.2 M 60.4 M 12.5 M 22.9 M 15.6 M 12.2 M 13.1 M

General and Administrative Expenses

20.6 M 18.4 M 11.1 M 13.6 M 13.4 M 13.7 M 13.6 M 3.95 M 4.76 M 4.23 M 4.09 M 3.37 M

All numbers in USD currency

Quarterly Income Statement Apollo Endosurgery

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 40.8 M - 39.7 M 39.5 M 29 M 27.3 M 26.3 M 25.8 M 23.1 M 21.2 M 21.1 M 21 M 21.4 M 21.9 M 21.9 M 21.9 M 21.9 M 18 M 17.3 M 17.3 M 15.5 M 10.7 M 10.7 M 10.7 M 335 K 334 K 325 K 756 K 2.1 M 1.48 M 19.7 M 19.2 M 16.2 M 15.9 M 14.5 M 13.4 M 13.4 M 13.4 M 13.4 M 13.1 M 11 M 76.9 M 9.56 M 8.66 M 9.01 M 62.9 M 62.7 M

Net Income

- -11.4 M - -8.41 M - -6.66 M -3.02 M -4.6 M - -2.6 M -6.25 M -10.3 M - -8.66 M -8.77 M -8.77 M - -9.76 M -9.54 M -8.13 M - -4.9 M -6.86 M -8.22 M - -5.93 M -9.52 M -6 M - -2.23 M -2.67 M -2.77 M - -3.17 M -3.73 M -3.3 M - -2.53 M -1.38 M -1.25 M - -1.1 M -647 K 646 K - 1.13 M 1.37 M -1.65 M

Revenue

- 19.6 M - 16.7 M - 16.4 M 16.6 M 13.9 M - 12.8 M 5.64 M 10.7 M - 11.3 M 14.3 M 13.2 M - 14.1 M 15.8 M 15.7 M - 16.5 M 17.1 M 14.5 M - 15.8 M 17.3 M 16.3 M - 61.3 K 748 K 784 K - 1.11 M 1.33 M 1.72 M - 2.55 M 2.02 M 1.11 M - 1.42 M 1.33 M 2.76 M - 1.78 M 1.54 M 2.78 M

Cost of Revenue

- 8.84 M - 7.29 M - 7.12 M 7.49 M 6.35 M - 5.84 M 3.22 M 5.08 M - 5.83 M 7.09 M 5.97 M - 6.4 M 6.61 M 6.55 M - 6.01 M 6.64 M 5.1 M - 5.25 M 9.19 M 4.91 M - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 10.7 M - 9.37 M - 9.23 M 9.12 M 7.51 M - 6.99 M 2.43 M 5.64 M - 5.43 M 7.17 M 7.24 M - 7.74 M 9.18 M 9.19 M - 10.5 M 10.5 M 9.42 M - 10.5 M 8.15 M 11.4 M - - - - - - - - - - - - - - - - - - - -

Operating Income

- -6.29 M - -7.25 M - -4.5 M -5.24 M -3.75 M - -1.57 M -4.3 M -6.68 M - -6.86 M -7.2 M -2.54 M - -8.1 M -7.51 M -7.63 M - -4.28 M -5.47 M -6.81 M - -3.72 M -6.26 M -3.02 M - -2.23 M -3.27 M -3.02 M - -3.57 M -4.33 M -3.1 M - -1.78 M -1.93 M -1.48 M - -1.35 M -1.08 M -1.23 M - -701 K -632 K 96 K

Interest Expense

- 1.16 M - 1.22 M - 1.34 M 1.33 M 1.35 M - 1.34 M 1.32 M 1.24 M - 1.22 M 669 K 959 K - 1 M 1.02 M 960 K - 1.01 M 1.05 M 1.48 M - 1.53 M 2.52 M 2.83 M - 40 40 - - 18 18 - - -420 27 K 27 K - -47.9 K 33.3 K -28.6 K - 31.2 K 4.11 K -43.6 K

EBITDA

- -5.98 M - -6.96 M - -4.22 M -4.88 M -3.32 M - -1.14 M -3.84 M -6.22 M - -6.42 M -6.72 M -2.04 M - -6.3 M -5.71 M -5.83 M - -2.48 M -3.64 M -5 M - -1.92 M -4.44 M -2.98 M - -1.96 M -3.13 M -2.95 M - -3.4 M -4.23 M -3.06 M - -1.62 M -1.8 M -1.43 M - -1.28 M -1.03 M -1.2 M - -635 K -595 K 117 K

Operating Expenses

- 17 M - 16.6 M - 13.7 M 14.4 M 11.3 M - 8.56 M 6.73 M 12.3 M - 12.3 M 14.4 M 9.79 M - 15.8 M 16.7 M 16.8 M - 14.8 M 15.9 M 16.2 M - 14.3 M 14.4 M 14.4 M - 2.29 M 4.02 M 3.81 M - 4.68 M 5.66 M 4.82 M - 4.33 M 3.95 M 2.59 M - 2.77 M 2.41 M 3.98 M - 2.48 M 2.17 M 2.68 M

General and Administrative Expenses

- 5.19 M - 5.23 M - 4.57 M 5.34 M 4.07 M - 2.37 M 2.16 M 3.34 M - 3.16 M 3.34 M 3.72 M - 3.02 M 3.25 M 3.32 M - 2.86 M 3.25 M 4.19 M - 3.84 M 2.33 M 2.64 M - 858 K 1.1 M 1.05 M - 1.05 M 1.08 M 1.16 M - 977 K 1.11 M 1 M - 1.07 M 873 K 882 K - 774 K 794 K 753 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company Apollo Endosurgery (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 39.27 -1.36 % $ 5.85 K usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 7.82 4.13 % $ 561 M israelIsrael
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 9.4 -2.49 % $ 1.27 B usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.99 -2.68 % $ 149 M franceFrance
CONMED Corporation CONMED Corporation
CNMD
$ 43.41 -5.2 % $ 1.35 B usaUSA
Electromed Electromed
ELMD
$ 23.98 -0.5 % $ 203 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
AxoGen AxoGen
AXGN
$ 29.83 -2.68 % $ 1.37 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.17 -3.35 % $ 110 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.5 -0.32 % $ 121 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.53 -4.57 % $ 54.5 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.8 6.81 % $ 43.5 M usaUSA
Align Technology Align Technology
ALGN
$ 182.64 -3.38 % $ 13.7 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Butterfly Network Butterfly Network
BFLY
$ 3.68 -4.42 % $ 779 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 113.61 -0.45 % $ 198 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 73.85 -3.11 % $ 109 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.98 -6.6 % $ 1.2 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 13.02 -3.34 % $ 1.95 B usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.6 -0.29 % $ 879 M israelIsrael
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 85.28 -2.18 % $ 49.9 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.43 1.42 % $ 23.1 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 104.29 0.53 % $ 1.32 B usaUSA